Stakeholders
Topics
Institute for Value-Based Medicine
About AJMC
CME/CE
Subscribe
- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018, 6(6):445-454. doi: 10.1016/S2213-8587(18)30075-5.
home / authors / saag-kg-wagman-rb-geusens-p-et-al-denosumab-versus-risedronate-in-glucocorticoid-induced-osteoporosis-a-multicentre-randomised-double-blind-active-controlled-double-dummy-non-inferiority-study-lancet-diabetes-endocrinol-2018
